← Back to Search

Virtual Care for Diabetes

N/A

Waitlist Available

Led By Adam White, MD

Research Sponsored by Endocrine Research Society

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 month intervals for 6 months

Awards & highlights

Study Summary

This trial is testing if diabetes care provided electronically can help people with diabetes in rural areas who don't have easy access to specialists.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ start and end of study (six months)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~start and end of study (six months)

This trial's timeline: 3 weeks for screening, Varies for treatment, and start and end of study (six months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

HbA1c

Secondary outcome measures

Survey of Healthcare Utilization

Survey of Quality of Life

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Interventional GroupExperimental Treatment1 Intervention

The recruited participants will be provided access to Virtual Care suite via internet and telephone communication.

Group II: Standard of CareActive Control1 Intervention

The recruited participants will receive the standard of diabetes care as offered by the services in their community.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Endocrine Research SocietyLead Sponsor

11 Previous Clinical Trials

483 Total Patients Enrolled

Adam White, MDPrincipal InvestigatorClinical Associate Professor, UBC

Monika Pawlowska, MDPrincipal InvestigatorClinical Assistant Professor, UBC

Media Library

Virtual Care Clinical Trial Eligibility Overview. Trial Name: NCT02681185 — N/A

Diabetes Research Study Groups: Interventional Group, Standard of Care

Diabetes Clinical Trial 2023: Virtual Care Highlights & Side Effects. Trial Name: NCT02681185 — N/A

Virtual Care 2023 Treatment Timeline for Medical Study. Trial Name: NCT02681185 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can individuals below four decades of age participate in this trial?

"Requirements for enrolment in this trial list a minimum age of 19 and maximum age of 75. Furthermore, there are 186 trials specifically targeting those under 18 years old, as well as 882 studies that focus on individuals over 65."

Answered by AI

What is the maximum number of individuals that can partake in this clinical experiment?

"Affirmative. The details posted on clinicaltrials.gov attest that this research trial is actively seeking subjects. Originally published on March 1st 2018, the study's information was last updated at the end of July 2022; it seeks to enroll a total of 100 individuals from one single medical facility."

Answered by AI

Are there any vacancies left for prospective participants in this research?

"That's right. According to clinicaltrials.gov, this investigation is currently enrolling patients. It was originally posted on the 1st of March 2018 and most recently revised on the 26th of July 2022; with a target sample size of 100 individuals at one location."

Answered by AI

Who is eligible to participate in this trial?

"This clinical trial requires 100 volunteers, aged 19 to 75, who suffer from diabetes mellitus. Additionally, candidates must possess the capacity to access and utilize the web on a desktop or mobile device; have Type 2 diabetes; and be able to reach a family doctor for routine blood tests."

Answered by AI

Recent research and studies

Diabetes Technology & TherapeuticsJournal

Self-monitoring of Blood Glucose (SMBG) in Insulin- and Non–insulin-using Adults with Diabetes: Consensus Recommendations for Improving SMBG Accuracy, Utilization, and Research

Hirsch, Irl B., Bruce W. Bode, Belinda P. Childs, Kelly L. Close, William A. Fisher, James R. Gavin III, Barry H. Ginsberg, Charles H. Raine III, and Carol A. Verderese. 2008. “Self-monitoring of Blood Glucose (SMBG) in Insulin- and Non–insulin-using Adults with Diabetes: Consensus Recommendations for Improving SMBG Accuracy, Utilization, and Research”. Diabetes Technology & Therapeutics. Mary Ann Liebert Inc. doi:10.1089/dia.2008.0104.

New England Journal of MedicineJournal

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

“Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes”. 2005. “Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes”. New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmoa052187.

The Diabetes EducatorJournal

AADE Position Statement

“AADE Position Statement”. 2006. “AADE Position Statement”. The Diabetes Educator. SAGE Publications. doi:10.1177/0145721706295873.

Diabetes CareJournal